Twitter Beğeni Hilesi

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dr Joseph McCollom DO 🇺🇸 Erman Akkus 🇹🇷 Gil Morgan, MD 🇺🇸 1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors

📣 Session 21 – The next speaker is Dr Joachim BROEKER from Boehringer Ingelheim who will talk about “Discovery of pan-KRAS Inhibitors BI-2865 and BI-2493”. Keep following us! 🔬💡 #EFMCISMC24 #MedChem

Follow this fantastic group of #ESMOAmbassadors: ready to bring you the highlights during #ESMO24. One click and you’ll have them all.

🚨🥁Just in time for ESMO - Eur. Oncology #ESMO24 meeting published in the October issue of Annals of Oncology 👉🏼 Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS #PrecisionOncology OncoAlert #ESMOambassadors annalsofoncology.org/article/S0923-…

Join us virtually on October 24 for the Global Policy Webinar focusing on The Growing Role and Current State of Patient Advocates in Cancer Research and Clinical Trial Design and Development: Real World Examples. Register now: nccn.org/global/global-…

At #ESMO24, #Natera and collaborators will present nine abstracts, including five posters from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. ow.ly/hybj50TmLOM

💊EGFR co-inhibition in KRAS-G12C CRC ✅Dramatic increase in ORR 👇 #ESMO24 ESMO - Eur. Oncology OncoAlert #cancer #oncology #MedX

RAS-PM Real World Data cohort analysis #ESMO24

Colin Lindsay (The Christie, Manchester) and colleagues have a review in press linking scientific insights and clinical challenges for Kras inhibitors in new combinations, and expansion to address KRas mutations beyond G12C. #ESMO24

Contact Mark Awad to support the understanding of pathways of resistance in KRAS-driven cancers #ESMO24 #SPARK

“In my opinion, after today, regardless of brain mets, the standard second line therapy should be T-DXd” says Cristina Saura of the ESMO - Eur. Oncology Guidelines as she discusses DESTINY-Breast12 #ESMO24

Dear Colleagues, Welcome to #ESMO24 !! There is no voice as important as that of our patient's, hence OncoAlert 🚨is proud to present our faculty Eva Schumacher-Wulf of Eva Schumacher-Wulf with the Patient Advocate Perspective in #BreastCancer here in Barcelona‼️ Breast Cancer

Stellar presentation by Cristiane D Bergerot about addressing sexual health in female and male pts with cancer. #ESMO24 ESMO - Eur. Oncology Educational Session Congratulations Matteo Lambertini, MD PhD

📢 Radiotherapy does not add to mFOLFIRINOX in borderline resectable #PancreaticCancer - ❎results for PRODIGE-44 #ESMO24 Good news for patients with PDAC - mFOLFIRINOX had ✅ outcomes (mOS 32.8m ➡️ 47.9m OS if resected). Results confirm ESMO - Eur. Oncology guidelines recommendations.

Up to 250 patients in the U.S. can remotely consent & participate to have plasma drawn locally.. Investigator(s) will compare mechanisms of acquired resistance across drugs & between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise NCT05272423

Telisotuzumab adizutecan (ABBV-400): A novel c-Met-targeting ADC #ESMO24

🚨 Join us at #ESMO24 today @ 6.30 PM, for our symposium exploring the emerging role of c-MET as a therapeutic target for ADCs in the treatment of lung and gastrointestinal cancers. Benjamin Besse Nicolas Girard , John Strickler, Eric Van Cutsem and myself! #LCSM #LungCancer